JPH01297059A - Warm heat sticking agent - Google Patents
Warm heat sticking agentInfo
- Publication number
- JPH01297059A JPH01297059A JP12938888A JP12938888A JPH01297059A JP H01297059 A JPH01297059 A JP H01297059A JP 12938888 A JP12938888 A JP 12938888A JP 12938888 A JP12938888 A JP 12938888A JP H01297059 A JPH01297059 A JP H01297059A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- heat
- water
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000853 adhesive Substances 0.000 claims abstract description 56
- 230000001070 adhesive effect Effects 0.000 claims abstract description 55
- 229920000642 polymer Polymers 0.000 claims abstract description 36
- 239000003208 petroleum Substances 0.000 claims abstract description 27
- 239000011347 resin Substances 0.000 claims abstract description 27
- 229920005989 resin Polymers 0.000 claims abstract description 27
- 125000002723 alicyclic group Chemical group 0.000 claims abstract description 22
- 229920000428 triblock copolymer Polymers 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 18
- -1 softener Substances 0.000 abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 239000003795 chemical substances by application Substances 0.000 abstract description 19
- 210000004243 sweat Anatomy 0.000 abstract description 15
- 230000028327 secretion Effects 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 7
- 229920001400 block copolymer Polymers 0.000 abstract description 5
- 229920001577 copolymer Polymers 0.000 abstract description 3
- 238000004132 cross linking Methods 0.000 abstract description 3
- 125000006841 cyclic skeleton Chemical group 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 229920001971 elastomer Polymers 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 239000002480 mineral oil Substances 0.000 abstract description 3
- 235000010446 mineral oil Nutrition 0.000 abstract description 3
- 229920003169 water-soluble polymer Polymers 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 230000035807 sensation Effects 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- NPERTKSDHFSDLC-UHFFFAOYSA-N ethenol;prop-2-enoic acid Chemical compound OC=C.OC(=O)C=C NPERTKSDHFSDLC-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 7
- 229940057995 liquid paraffin Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 6
- 239000012790 adhesive layer Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000020169 heat generation Effects 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 238000010792 warming Methods 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229950002568 bucumolol Drugs 0.000 description 4
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 229960002508 pindolol Drugs 0.000 description 4
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000004902 Softening Agent Substances 0.000 description 3
- 208000010040 Sprains and Strains Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 2
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 2
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 2
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 2
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 2
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 229920004939 Cariflex™ Polymers 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 2
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 2
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
- 229910052977 alkali metal sulfide Inorganic materials 0.000 description 2
- 229960002213 alprenolol Drugs 0.000 description 2
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229960003099 amcinonide Drugs 0.000 description 2
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 2
- 229960004335 azelastine hydrochloride Drugs 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 2
- 229960000330 bupranolol Drugs 0.000 description 2
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 2
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 2
- 229960001590 butorphanol tartrate Drugs 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229940007061 capsicum extract Drugs 0.000 description 2
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000456 carbinoxamine maleate Drugs 0.000 description 2
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 2
- 229960001222 carteolol Drugs 0.000 description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 2
- 229940106681 chloroacetic acid Drugs 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 2
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 229960003932 cloxazolam Drugs 0.000 description 2
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 2
- 229960004415 codeine phosphate Drugs 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 2
- 229960001056 dimemorfan Drugs 0.000 description 2
- 229940099401 dimethindene maleate Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 229960000309 enalapril maleate Drugs 0.000 description 2
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 2
- 229960002336 estazolam Drugs 0.000 description 2
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 2
- 229950004659 estradiol enanthate Drugs 0.000 description 2
- 229950007164 ethiazide Drugs 0.000 description 2
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 2
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960002679 fentiazac Drugs 0.000 description 2
- 229960004930 fludiazepam Drugs 0.000 description 2
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229950009354 flutazolam Drugs 0.000 description 2
- 229940050411 fumarate Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 2
- 229950005954 ibuprofen piconol Drugs 0.000 description 2
- 229950008838 indenolol Drugs 0.000 description 2
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000011256 inorganic filler Substances 0.000 description 2
- 229910003475 inorganic filler Inorganic materials 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960003517 isothipendyl Drugs 0.000 description 2
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 229960003630 ketotifen fumarate Drugs 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960003739 methyclothiazide Drugs 0.000 description 2
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 2
- 229960002817 metolazone Drugs 0.000 description 2
- 229950000412 mexazolam Drugs 0.000 description 2
- ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 2
- 229960004027 molsidomine Drugs 0.000 description 2
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 2
- 229960002497 nicorandil Drugs 0.000 description 2
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 2
- 229950001981 nimetazepam Drugs 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 229960004535 oxazepam Drugs 0.000 description 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
- 229950006124 oxazolam Drugs 0.000 description 2
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 2
- 229960004570 oxprenolol Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 2
- 229960005301 pentazocine Drugs 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- 229960004856 prazepam Drugs 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 2
- 229960002789 procaterol hydrochloride Drugs 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 229960000896 tipepidine Drugs 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 2
- 229960004747 ubidecarenone Drugs 0.000 description 2
- 229950010121 ufenamate Drugs 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- 229960003859 efloxate Drugs 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は人体皮膚に適用することを目的とした自若性の
優れた温熱貼付剤並びに発熱部材用粘着剤を提供するこ
とにある。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The object of the present invention is to provide a thermal patch and a pressure-sensitive adhesive for a heat-generating member, which are intended to be applied to human skin and have excellent self-replicability.
従来より、空気又は酸素の存在によって発熱する発熱層
及び粘着層からなる、温熱貼付剤が検討されている。例
えば特開昭５０−５４１８８号には鉄粉等よりなる発熱
部材と湿布部材よりなる温湿布構造物が、特開昭５３−
４７１５４号にはアルカリ金属の硫化物よりなる発熱剤
と湿布剤よりなる温熱湿布剤が、更に特開昭６２−１０
３０１４号には発熱体と粘着剤を組み合わせた温熱プラ
スターが、それぞれ開示されている。BACKGROUND ART A thermal patch consisting of a heat generating layer and an adhesive layer that generate heat in the presence of air or oxygen has been studied. For example, JP-A-50-54188 discloses a hot compress structure consisting of a heat-generating member made of iron powder or the like and a compress member.
No. 47154 discloses a heating poultice consisting of an exothermic agent made of an alkali metal sulfide and a poultice;
No. 3014 discloses a thermal plaster that combines a heating element and an adhesive.
しかし、これらの温熱貼付剤において、イ）粘着力が弱
いため、皮膚に貼付する場合粘着テープ等で止める補助
手段が必要である。However, these thermal patches have (a) weak adhesive strength, so when they are applied to the skin, an auxiliary means such as adhesive tape is required to fix them.
口）湿布剤にあっては含有する水の影響のため熱伝導が
悪く貼付時に冷感を感じ、更に温感を惑しるまでのラグ
タイムがある。A) Poultices have poor heat conduction due to the influence of the water they contain, making you feel cold when applied, and there is also a lag time that can confuse your sense of warmth.
ハ）油性の粘着剤を用いた場合、剥離時の角質剥離によ
る気触れが発生する場合がある。c) If an oil-based adhesive is used, there may be a feeling of discomfort due to exfoliation of the dead skin during peeling.
二）湿布剤と皮膚との間に、発熱による汗等の分泌物が
貯留しこれが気触れの原因となる。2) Secretions such as sweat due to fever accumulate between the poultice and the skin, causing irritation.
ホ）発熱により、皮膚と接触している粘着剤に変化が起
き、ダレ、膏体のはみだし等が起きる場合がある。e) Due to heat generation, changes may occur in the adhesive that is in contact with the skin, resulting in sagging, oozing of the paste, etc.
等の問題があり、未だ理想的な温熱貼付剤並びに発熱部
材用粘着剤が出現していないのが現状である。Due to these problems, the current situation is that ideal thermal patches and adhesives for heat-generating members have not yet appeared.
そこで本願発明者らは、これらの問題を解決するために
鋭意研究を重ねた結果、Ａ−Ｂ−Ａ型ブロック共重合体
、脂環族系石油樹脂、軟化剤及び吸水高分子よりなる粘
着剤を使用することで、１、貼付時より温感を感じる熱
伝導性を保持２、皮膚の動きに追従しうる柔らかい粘着
特性
３、気触れの原因となる汗等の分泌物を吸収する
４、熱に対して安定であり、ダレ、膏体のはみだし等が
ない
５、皮膚に対する副作用（気触れ）の緩和等の特性を保
持した、まさに理想的な温熱貼付剤並びに発熱部材用粘
着剤となることを見い出し、本発明としたのである。In order to solve these problems, the inventors of the present application have conducted intensive research and found that an adhesive consisting of an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, and a water-absorbing polymer. By using , 1. It maintains thermal conductivity that makes you feel warm when applied. 2. It has soft adhesive properties that can follow the movement of the skin. 3. It absorbs secretions such as sweat that can cause skin irritation. 4. It is stable against heat, has properties such as no sagging or extrusion of the paste5, and alleviates side effects (feelings) on the skin, making it an ideal thermal patch and adhesive for heat-generating components. This discovery was made into the present invention.
本発明は、温熱貼付剤並びに発熱部材用粘着剤に最も適
した粘着剤を見い出し温熱貼付剤としたことにある。The present invention consists in finding an adhesive that is most suitable for a thermal patch and an adhesive for a heat-generating member, and making it into a thermal patch.
次に本発明の構成成分について詳しく説明する。Next, the constituent components of the present invention will be explained in detail.
Ａ−Ｂ−Ａ型ブロック共重合体とは、モノビニル置換芳
香族化合物Ａと共役ジオレフィン共重合体Ｂとのブロッ
ク共重合体であり、具体的にはカリフレックスＴＲ−１
１０１、カリフレックスＴＲ−１，１０７、カリフレッ
クスＴＲ−１１１１（シェル化学製）等、フィリップベ
トロリアム製のツルプレン４１８等であり、その配合量
は粘着剤組成物中１０〜３０重量部であり、好ましくは
１５〜２５重量部である。The A-B-A type block copolymer is a block copolymer of monovinyl-substituted aromatic compound A and conjugated diolefin copolymer B, and specifically, Cariflex TR-1
101, Kaliflex TR-1, 107, Kaliflex TR-1111 (Shell Chemical Co., Ltd.), Turprene 418 manufactured by Philips Vetrolium, etc., and the amount thereof is 10 to 30 parts by weight in the adhesive composition. , preferably 15 to 25 parts by weight.
吸水高分子とは、自重の１０倍以上の水を吸収しゲル化
膨潤するものであり、例えば水溶性ポリマーに軽度な架
橋結合を導入した吸水高分子が、適宜単独もしくは２種
以上の混合でもって処方される。具体的にはサンウェッ
トＩＭ−３００、サンウェットＩＭ−３００ＭＰＳ、サ
ンウェット■Ｍ−１０００、サンウェットＩＭ−１００
０ＭＰＳ（三洋化成製）等、アクアキープ４Ｓ、アクア
キープ４ＳＨ（製鉄化学製）等、スミカゲル５Ｐ−５２
０、スミカゲルＮ−１０４０（住友化学製）等、ＫＩゲ
ル２０１−に、Ｋｌゲル−２０１に−Ｆ２（クラレ製）
等、アラソーブ８００１アラソーブ８００Ｆ （荒用化
学製）等であり、中でもサンウェットＩＭ−３００ＭＰ
Ｓ、サンウェットＩＭ−１０００ＭＰＳ、スミカゲルＮ
Ｐ−１０２０、スミカゲルＮＰ−１０４０ＳＫｌゲル−
２０１に−Ｆ２、アラソーブ８００Ｆ等は特に好ましい
。配合量としては、粘着剤組成物中１〜１０重量部であ
り、好ましくは２〜８重量部である。A water-absorbing polymer is one that absorbs more than 10 times its own weight of water and gels and swells. For example, a water-absorbing polymer that has a mild crosslinking bond introduced into a water-soluble polymer can be used alone or as a mixture of two or more. It is prescribed. Specifically, Sunwet IM-300, Sunwet IM-300MPS, Sunwet M-1000, Sunwet IM-100.
0MPS (manufactured by Sanyo Chemical Co., Ltd.), Aqua Keep 4S, Aqua Keep 4SH (manufactured by Steel Chemical Co., Ltd.), etc., Sumikagel 5P-52
0, Sumikagel N-1040 (manufactured by Sumitomo Chemical), etc., KI gel 201-, KI gel-201-F2 (manufactured by Kuraray)
etc., Arasorb 8001 Arasorb 800F (manufactured by Arayo Kagaku), among others, Sunwet IM-300MP.
S, Sunwet IM-1000MPS, Sumikagel N
P-1020, Sumikagel NP-1040SKl gel-
201, -F2, Arasorb 800F, etc. are particularly preferred. The blending amount is 1 to 10 parts by weight, preferably 2 to 8 parts by weight, in the pressure-sensitive adhesive composition.
脂環族系石油樹脂とは、環状骨格を持った石油系樹脂で
あり、具体的にはアルコンＰ−８５、アルコンｐ−１ｏ
ｏ、アルコンＰ−１２５（荒用化学製）等、フィントン
（日本ゼオン製）、エスコレッツ３０００ （エクソン
製）等であり、その配合量は１０〜５０重量部であり、
好ましくは２５〜４５重量部である。Alicyclic petroleum resin is a petroleum resin with a cyclic skeleton, specifically Alcon P-85, Alcon p-1o
o, Alcon P-125 (manufactured by Arayo Kagaku), etc., Finton (manufactured by Nippon Zeon), Escorez 3000 (manufactured by Exxon), etc., and the blending amount is 10 to 50 parts by weight,
Preferably it is 25 to 45 parts by weight.
軟化剤としては、高級脂肪酸、液化ゴム、鉱油等が用い
られ、その配合量としては、１０〜５０重量部、好まし
くは２５〜４５重量部である。As the softening agent, higher fatty acids, liquefied rubber, mineral oil, etc. are used, and the amount thereof is 10 to 50 parts by weight, preferably 25 to 45 parts by weight.
その他使用目的に応じて、従来公知の老化防止剤、無機
充填剤、酸化防止剤等が適宜適量配合される。In addition, conventionally known anti-aging agents, inorganic fillers, antioxidants, etc. may be blended in appropriate amounts depending on the purpose of use.
以上のようにして、得られた粘着剤を発熱部材と組み合
わせて、本願発明の温熱貼付剤とするわけであるが、こ
こで発熱部材の種類は別に制約はなく、従来公知の発熱
を有する部材であればすべて適用できるものである。As described above, the obtained adhesive is combined with a heat-generating member to obtain the thermal patch of the present invention. However, there is no particular restriction on the type of heat-generating member, and conventionally known heat-generating members may be used. All are applicable.
例えば電気利用の発熱部材、乾電池又は太陽電池等を使
用した発熱部材又はペーパー状の電池、あるいはもぐさ
や昔から使用されているカイロ部材や化学発熱を利用し
た発熱カイロ等が挙げられる。又、化学発熱を利用した
発熱カイロの原料としては、例えば特開昭５０−１０５
５６２号公報、実開昭５０−９７２８９号公報、特開昭
５０−２３０６４号公報、特開昭５０−４０４７７号公
報、実開昭５５−５９６１６号公報、特公昭６０−１２
３８１号公報、特公昭６１−８１１６号公報、特公昭６
３−２４０３０号公報等に記載のものが使用されるが、
これら引用公報記載のものに限定はされず、これら以外
の公報又は文献記載のものも当然使用される。尚、本発
明における発熱部材として特に好ましいのは、化学発熱
型の発熱カイロ型のものが携帯上より便利である。その
組成としては鉄粉系、反応助剤、水及び保水剤から構成
されるもので、空気及び水の共存下で発熱を生起する物
質が好んで使用される。具体的には鉄粉、還元鉄粉、活
性炭、アルミナ、シリカゲル、木炭、吸水性高分子、塩
化ナトリウム、塩化カリウム、塩化マグネシウム、塩化
鉄、酢酸、クロル酢酸、水、アクリル系吸水高分子等の
発熱原料を適宜配合処方した組成物であり、本発明にお
いて使用する発熱剤量は１〜２ｇ／ｅＩｌｌ程度が適当
である。又、発熱剤の温度条件としては粘着剤層の熱安
定性を破壊しないことがもっとも重要であり、極度の高
温状態は好ましくない。そこで、本発明の温度設定とし
ては粘着剤表面温度が６０℃以下がよく、好ましくは５
０℃以下、更に好ましい状態としては４５℃以下がもっ
ともよい、又、遠赤外線効果を期待するうえで発熱組成
中にセラミックスの含有や発熱部材層と粘着剤層の間に
セラミックスを挿入した層を設けてもよい。Examples include heat-generating members using electricity, heat-generating members using dry batteries or solar cells, or paper batteries, warmer members that have been used for a long time, and heat-generating body warmers that utilize chemical heat generation. In addition, as raw materials for heat-generating hand warmers that utilize chemical heat generation, for example, Japanese Patent Application Laid-Open No. 50-105
No. 562, Japanese Utility Model Publication No. 50-97289, Japanese Unexamined Utility Model Publication No. 50-23064, Japanese Unexamined Utility Model Publication No. 50-40477, Japanese Utility Model Application No. 55-59616, Japanese Unexamined Utility Model Publication No. 60-12
381 Publication, Special Publication No. 61-8116, Special Publication No. 1983
The ones described in Publication No. 3-24030 etc. are used, but
The invention is not limited to those described in these cited publications, and of course those described in other publications or literature may also be used. It should be noted that a particularly preferred heat generating member in the present invention is a chemical heating type heat generating body warmer type, which is more convenient to carry. Its composition consists of iron powder, a reaction aid, water, and a water retention agent, and substances that generate heat in the coexistence of air and water are preferably used. Specifically, iron powder, reduced iron powder, activated carbon, alumina, silica gel, charcoal, water-absorbing polymers, sodium chloride, potassium chloride, magnesium chloride, iron chloride, acetic acid, chloroacetic acid, water, acrylic water-absorbing polymers, etc. It is a composition in which exothermic raw materials are appropriately mixed and formulated, and the appropriate amount of exothermic agent used in the present invention is about 1 to 2 g/eIl. Furthermore, the most important temperature condition for the exothermic agent is not to destroy the thermal stability of the adhesive layer, and extremely high temperatures are not preferred. Therefore, the temperature setting of the present invention is such that the adhesive surface temperature is preferably 60°C or less, preferably 50°C or less.
The best temperature is 0°C or lower, more preferably 45°C or lower.Also, in order to expect a far-infrared effect, it is recommended to include ceramics in the heat-generating composition or a layer with ceramics inserted between the heat-generating member layer and the adhesive layer. It may be provided.
このようにして得られた温熱貼付剤は、肩こり、腰痛、
打ち身、捻挫等の疾患に使用され、温熱による治療効果
を充分期待できるものであり、又、使用上特に問題を生
じていた気触れの発生を、本発明の温熱貼付剤に吸汗性
を持たせることにより著しく抑制させたものである。The thermal patch obtained in this way can be used to treat stiff shoulders, lower back pain,
The thermal patch of the present invention is used for diseases such as bruises and sprains, and can be expected to have a sufficient therapeutic effect due to heat.The thermal patch of the present invention has sweat absorption properties to prevent the occurrence of skin sensation, which has been a particular problem during use. This has significantly suppressed the
又、薬物としては経皮吸収可能な薬物を含有させ、温熱
医療用貼付剤として用いることができる。In addition, a transdermally absorbable drug may be included as a drug, and it can be used as a thermal medical patch.
例えば、皮膚刺激剤及び鎮痛消炎剤として、サリチル酸
、サリチル酸メチル、サリチル酸グリコール、ｌ−メン
トール、カンフル、ハツカ油、チモール、ニコチン酸ベ
ンジルエステル、トウガラシエキス、カブサイシン、ノ
ニル酸ワニアルアミド、フルビナク、フルフェナム酸ブ
チル、ピロキシカム、インドメタシン、ケトプロフェン
、プラノプロフェン、フエブラゾン、ロキソプロフェン
、アンツェナフナトリウム、オキサプロジン、エモルフ
ァゾン、フェンチアザツク、ジクロツェナフナトリウム
、ジフルニサール、イブプロフェンピコノール、ベンダ
ザック、及びスブロフエン、並びにこれらのエステル誘
導体、あるいは塩酸ブブレノルフィン、ペンタゾシン、
酒石酸ブトルファノール等。For example, as skin irritants and analgesic anti-inflammatory agents, salicylic acid, methyl salicylate, glycol salicylate, l-menthol, camphor, peppermint oil, thymol, benzyl nicotinic acid ester, capsicum extract, cabsaicin, nonylic acid wanialamide, flubinac, butyl flufenamate, Piroxicam, indomethacin, ketoprofen, pranoprofen, fuebrazone, loxoprofen, anzenaf sodium, oxaprozin, emorfazone, fentiazac, diclozenaf sodium, diflunisal, ibuprofen piconol, bendazac, and subrofen, and their ester derivatives, or bubrenorphine hydrochloride , pentazocine,
butorphanol tartrate etc.
中枢神経作用剤（睡眠鎮静剤、抗てんかん剤、精神神経
用剤）として、フルフェナジン、チオリダジン、ジアゼ
パム、クロルプロマジン、ニトラゼバム、エスタゾラム
、トリアゾラム、ニメタゼパム、フルニトラゼバム、ハ
ロセキサシラム、フルラゼパム、クロナゼパム、プロベ
リジアジン、プロクロルペラジン、アルブラシラム、オ
キサゼパム、オキサゾラム、クロキサゾラム、プラゼパ
ム、フルタゾラム、メキサゾラム、ロラゼパム、フルジ
アゼパム、プロマゼバム、メタゼパム等。Central nervous system acting agents (sedative sleep agents, anti-epileptic drugs, psychiatric drugs) include fluphenazine, thioridazine, diazepam, chlorpromazine, nitrazebam, estazolam, triazolam, nimetazepam, flunitrazebam, halosexacillam, flurazepam, clonazepam, proberidiazine, prochlorpera. Gin, albrasulam, oxazepam, oxazolam, cloxazolam, prazepam, flutazolam, mexazolam, lorazepam, fludiazepam, promazebam, metazepam, etc.
利尿剤としてハイドロサイアザイド、ペンドロフルナサ
イアザイド、エチアジド、シクロベンチアジド、ヒドロ
クロロチアジド、ペンフルチド、メチクロチアジド、フ
ロセミド、メトラゾン、ボリチアシト、ペンドロフルメ
チアジド等。Diuretics include hydrothiazide, pendroflunathiazide, ethiazide, cyclobenziazide, hydrochlorothiazide, penflutide, methyclothiazide, furosemide, metolazone, volithiacit, pendroflumethiazide, etc.
血圧降下剤として、クロニジン、アルサーオキシロン、
レシナミン、メシル酸ジヒドロエルゴトキシン、レセル
、ピンプラゾシン、カプトプリル、ピンドロール、マレ
イン酸エナラプリル等。As antihypertensive agents, clonidine, altheroxirone,
Resinamine, dihydroergotoxin mesylate, Resel, pinprazosin, captopril, pindolol, enalapril maleate, etc.
冠血管拡張剤としてニトログリセリン、ニトログリコー
ル、イソソルバイトシナイトレート、塩酸ババベリン、
ジピリダモール、エフロキサ−１・、トリメタシン、ニ
コランジル、シンナリジン、ナイリドン、モルシドミン
ニフエジピン等。Coronary vasodilators include nitroglycerin, nitroglycol, isosorbite cinitrate, bababerine hydrochloride,
Dipyridamole, efloxa-1, trimethacin, nicorandil, cinnarizine, nyridone, molsidomine nifedipine, etc.
鎮咳去痰剤としてリン酸コデイン、リン酸ジヒドロコデ
イン、塩酸エフェドリン、塩酸クロルプレナリン、臭化
水素酸フェノチロール、硫酸サルブタモール、リン酸ジ
メモルファン、塩酸アゼラスチン、塩酸クレンブテロー
ル、塩酸ツロブテロール、塩酸トリメトキノール、塩酸
プロカテロール、塩酸ブロムヘキシン、トラニラスト、
ヒベンズ酸チペピジン、フマル酸ケトチフエン、フマル
酸フォルモチロール、リン酸ペンスプロベリン、グリチ
ルレチン酸等。As an antitussive expectorant: codeine phosphate, dihydrocodeine phosphate, ephedrine hydrochloride, chlorprenaline hydrochloride, phenotyrol hydrobromide, salbutamol sulfate, dimemorphan phosphate, azelastine hydrochloride, clenbuterol hydrochloride, tulobuterol hydrochloride, trimethoquinol hydrochloride, procaterol hydrochloride, Bromhexine hydrochloride, tranilast,
Tipepidine hibenzate, ketotifen fumarate, formotyol fumarate, pensproveline phosphate, glycyrrhetinic acid, etc.
抗ヒスタミン剤として塩酸ジフェンヒドラミン、塩酸ト
リプロリジン、塩酸イソチペンジル、塩酸プロメタシン
、マレイン酸クロルフェニラミン、塩酸シプロへブタジ
ン、フマル酸タレマスチン、マレイン酸カルビノキサミ
ン、マレイン酸ジメチンデン等。Antihistamines include diphenhydramine hydrochloride, triprolidine hydrochloride, isothipendyl hydrochloride, promethacin hydrochloride, chlorpheniramine maleate, cyprohebutadine hydrochloride, talemastine fumarate, carbinoxamine maleate, dimethindene maleate, etc.
不整脈用剤としてアルプレノロール、オクスプレノロー
ル、ブクモロール、ブプラノロール、ピンドロール、イ
ンデノロール、カルテオロール、ブクモロール、プロプ
ラノロール、チモロール等。Arrhythmia agents include alprenolol, oxprenolol, bucumolol, bupranolol, pindolol, indenolol, carteolol, bucumolol, propranolol, timolol, etc.
強心剤としてジキタリス、ユビデカレノン、ジゴキシン
、メチルジゴキシン、デストラノシド等。Cardiotropes include digitalis, ubidecarenone, digoxin, methyldigoxin, and destranoside.
性ホルモンとしてエストラジオールエナンテート、エス
トラジオールシビネート、レボノルゲストレル、エスト
ラジオール等。Estradiol enanthate, estradiol cibinate, levonorgestrel, estradiol, etc. as sex hormones.
副腎皮膚ホルモン剤として酢酸ヒドロコルチゾン１、ヒ
ドロコルチゾン、プレドニゾロン、ドリアムシノロンア
セトニド、デキサメタシンリン酸エステル、メチルプレ
ドニゾロン、酢酸ダイクロリンアセトニド、酢酸デキサ
メタシン、デキサメタシン、フルオロメトロン、リン酸
ベタメタシンナトリウム、ベタメタシン、吉草酸ベタメ
タシン、プロピオン酸ベクロメタゾン、フルドロキシコ
ルチド、酪酸ヒドロコルチゾン、ジプロピオン酸ベタメ
タヅン、フルオシノニド、プロピオン酸クロベタゾール
、吉草酸ジフルコルトロン、ハルジノニド、アムシノニ
ド、吉草酸プレドニゾロン等。Adrenal skin hormones include hydrocortisone acetate 1, hydrocortisone, prednisolone, doriamcinolone acetonide, dexamethacin phosphate, methylprednisolone, dichlorine acetate, dexamethacin acetate, dexamethacin, fluorometholone, betamethacin sodium phosphate, betamethacin , betamethacin valerate, beclomethasone propionate, fludroxycortide, hydrocortisone butyrate, betamethadone dipropionate, fluocinonide, clobetasol propionate, diflucortolon valerate, haldinide, amcinonide, prednisolone valerate, etc.
局所麻酔剤としてリドカイン、アミノ安息香酸エチル、
塩酸ブロカイン、ジブカイン、プロ力イン等が挙げられ
る。lidocaine, ethyl aminobenzoate, as a local anesthetic;
Examples include brocaine hydrochloride, dibucaine, procaine, and the like.
これら薬効成分は、一種又は必要に応じて二種以上配合
されて用いられる。These medicinal ingredients may be used alone or in combination of two or more as necessary.
配合量としては薬効を期待できる量が好ましく、粘着剤
全体を１００重量部とした場合、０．００１〜２０重量
部の範囲内で適宜処方される。又、湿布薬として使用可
能な漢方薬のエキス、粉体等も当然使用できるものであ
る。The blending amount is preferably an amount that can be expected to have a medicinal effect, and is appropriately formulated within the range of 0.001 to 20 parts by weight when the entire adhesive is 100 parts by weight. Naturally, extracts, powders, etc. of Chinese herbal medicines that can be used as poultices can also be used.
このようにして薬効成分を配合した粘着剤を付与した温
熱貼付剤は特に長時間貼付しても気触れの原因と考えら
れる汗を充分に吸収するため、その発生を著しく抑制す
るものである。又、温熱効果もあり、人体皮膚に対する
薬物の経皮吸収が一段と向上し、薬効発現性が速く治療
効果においても好ましいものである。The thermal patch to which the adhesive containing medicinal ingredients has been applied in this way sufficiently absorbs sweat, which is considered to be the cause of dryness, even if it is applied for a long period of time, thereby significantly suppressing the occurrence of sweat. In addition, it has a thermal effect, which further improves the transdermal absorption of drugs into the human skin, and the onset of drug efficacy is fast, which is preferable in terms of therapeutic effects.
次に製造法としては、従来公知の方法で良く、例えばニ
ーダ−、ミキサー等の混練機を用い、１２０〜１６０℃
程度の温度で混練し、シート基材に展延するか、もしく
はいったん剥離処理の施された紙、フィルム等に展延し
、その後使用される基材に圧着転写して得られた粘着シ
ートを発熱体として張り合わせて製造することもできる
。Next, as a production method, a conventionally known method may be used, for example, using a kneader such as a kneader or mixer, and at a temperature of 120 to 160 °C.
The resulting adhesive sheet is kneaded at a certain temperature and spread on a sheet base material, or is first spread on release-treated paper, film, etc., and then pressure-transferred to the base material to be used. It can also be manufactured by laminating them together as a heating element.
このようにして製造された、温熱貼付剤は最終的には気
密性の包装形態で処理されることが望ましいものである
が、これは発熱体の発熱の仕方に応じた包装形態の対応
を取る必要があり、特に限定されるものではない。It is desirable that the thermal patch produced in this way is ultimately packaged in an airtight package, but the packaging should be adapted to the way the heating element generates heat. It is necessary and is not particularly limited.
以上、上述した本発明の温熱貼付剤は、以下の試験例、
実施例で述べる如く、
１）Ａ−Ｂ−Ａ型ブロック共重合体１０〜３０重量部
２）吸水高分子１〜１０重量部
３）脂環族系石油樹脂１０〜５０重量部４）軟化剤１０
〜５０重量部
又は１）〜４）の組成物に薬物配合による粘着剤が必須
であり、これを発熱体と組み合わせることにより、
■早い温域発現
■皮膚に追従しうる柔らかい粘着特性
■汗等の分泌物の吸収
■熱に対して安定な特性
■皮膚に対する副作用（気触れ等）の緩和等の特徴を有
し、正に理想的な温熱貼付剤並びに発熱部材用粘着剤と
なるのである。As mentioned above, the thermal patch of the present invention described above was tested in the following test examples,
As described in the examples, 1) 10 to 30 parts by weight of A-B-A type block copolymer 2) 1 to 10 parts by weight of water-absorbing polymer 3) 10 to 50 parts by weight of alicyclic petroleum resin 4) Softener 10
~50 parts by weight or an adhesive compounded with a drug in the composition of 1) to 4) is essential, and by combining this with a heating element, ■ Fast temperature development ■ Soft adhesive properties that can follow the skin ■ Sweat, etc. It has characteristics such as absorption of secretions, stability against heat, and alleviation of side effects on the skin (sensitivity, etc.), making it an ideal thermal patch and adhesive for heat-generating components.
次に、上述の作用及び効果を実施例及び試験例により更
に詳しく説明する。Next, the above-mentioned functions and effects will be explained in more detail using Examples and Test Examples.
実施例１
Ａ−Ｂ−Ａ型ブロック共重合体としてカリフレックスＴ
Ｒ−１１０７（シェル化学製）２５重量部と軟化剤とし
て流動パラフィン３０重量部、脂環族系石油樹脂として
アルコン（荒用化学製）４０重量部をニーグー中１６０
℃にて混練、その後吸水高分子としてサンウェットＩＭ
−３００ＭＰＳ（三洋化成製）５重量部を添加混合し、
不織布に３５０μ鳳の厚さになるように展延したものを
、所望の大きさに切断後、発熱体と張り合わせ本願発明
の温熱貼付剤とした。このものを貼付したところ、貼付
後３分で温感を感じ初め、６時間にわたって適度な温感
が持続した。又、剥離後の皮膚気触れも皆無であった。Example 1 Califlex T as an A-B-A type block copolymer
25 parts by weight of R-1107 (made by Shell Chemical Co., Ltd.), 30 parts by weight of liquid paraffin as a softener, and 40 parts by weight of Alcon (made by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin were mixed in 160 parts by weight of Niegu.
Knead at ℃, then use Sunwet IM as a water-absorbing polymer.
- Add and mix 5 parts by weight of 300MPS (manufactured by Sanyo Chemical),
The nonwoven fabric was spread to a thickness of 350 μm, cut into desired sizes, and then laminated with a heating element to form the thermal patch of the present invention. When this product was applied, a warm sensation began to be felt 3 minutes after application, and a moderate warm sensation continued for 6 hours. Moreover, there was no skin irritation after peeling.
実施例２
Ａ−Ｂ−Ａ型ブロック共重合体としてカリフレックスＴ
Ｒ−１１０７（シェル化学製）２２重量部と添加剤とし
て流動パラフィン３３重量部、脂環族系石油樹脂として
アルコン（荒用化学製）３７重量部をニーグー中１５０
℃にて混練、その後酸化チタン３重量部と吸水高分子と
してサンウェッ１−ＩＭ−３００ＭＰＳ （三洋化成製
）５重量部を添加今後し、実施例１と同様に処理して本
発明の温熱貼付剤とした。皮膚に貼付したところ実施例
１と同様であった。Example 2 Califlex T as an A-B-A block copolymer
22 parts by weight of R-1107 (made by Shell Chemical Co., Ltd.), 33 parts by weight of liquid paraffin as an additive, and 37 parts by weight of Alcon (made by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin were mixed in 150 parts by weight of Niegu.
After kneading at ℃, 3 parts by weight of titanium oxide and 5 parts by weight of Sunwet 1-IM-300MPS (manufactured by Sanyo Chemical Co., Ltd.) as a water-absorbing polymer were added and treated in the same manner as in Example 1 to obtain a thermal patch of the present invention. And so. When applied to the skin, the result was the same as in Example 1.
参考例１
ゼラチン ４重量部ポリアクリル酸
ソーダ ５重量部グリセリン ２
０重量部ポリビニルピロリドン １重量部カオリ
ン １５重量部水
残部
上記の組成により、湿布剤を作成し、実施例１と同様に
して、温熱貼付剤とした。Reference example 1 Gelatin 4 parts by weight Sodium polyacrylate 5 parts by weight Glycerin 2
0 parts by weight Polyvinylpyrrolidone 1 part by weight Kaolin 15 parts by weight Water
A poultice was prepared using the remaining composition as described above, and a thermal patch was prepared in the same manner as in Example 1.
参考例２
カリフレックスＴＲ−１１０７２０重量部流動パラフィ
ン ２４重量部水添ロジン
３０重量部吸水性高分子 １重量部上記
の組成により、実施例１と同様に処理して温熱貼付剤と
した。Reference example 2 Cauliflex TR-110720 parts by weight liquid paraffin 24 parts by weight hydrogenated rosin
30 parts by weight Water-absorbing polymer 1 part by weight With the above composition, a thermal patch was prepared in the same manner as in Example 1.
試験例１ （温感試験）
ボランティアの背中に本発明の実施例１及び参考例１の
温熱貼付剤を貼付し、その皮膚温度変化を温度センサー
にて測定した。その結果を表１に示す。Test Example 1 (Warming sensation test) The thermal patches of Example 1 and Reference Example 1 of the present invention were applied to the backs of volunteers, and changes in skin temperature were measured using a temperature sensor. The results are shown in Table 1.
表１
表１に示す通り、本発明の温熱貼付剤は、参考例に比較
し、早い温域発現を如実に示しており、本発明温熱貼付
剤並びに発熱部材用粘着剤の優秀さを裏付けるものであ
った。Table 1 As shown in Table 1, the thermal patch of the present invention clearly shows a faster temperature range development compared to the reference example, which supports the excellence of the thermal patch of the present invention and the adhesive for heat-generating components. Met.
試験例２ （吸水力試験）
各試験サンプル（実施例１．２及び比較例１より発熱体
を除いたもの）５Ｘ５ｃｍのものを水中に浸し、８時間
後に取り出しその重量を測定し、増加した重量を元の重
量で除し、吸水した量を表２に示す。（尚、比較例１と
は、実施例１より吸水高分子を除いたものである。）
表２
結果より明らかな如く、本発明の粘着剤は、比較例に比
べきねだった吸水力を示した。Test Example 2 (Water Absorption Power Test) Each test sample (Example 1.2 and Comparative Example 1 without the heating element) 5 x 5 cm was immersed in water, taken out after 8 hours and its weight was measured, and the increased weight was determined. Table 2 shows the amount of water absorbed by dividing by the original weight. (Comparative Example 1 is the same as Example 1 except that the water-absorbing polymer was removed.) Table 2 As is clear from the results, the adhesive of the present invention has a greater water-absorbing power than the Comparative Example. Indicated.
試験例３ （耐熱性試験）
各試験サンプルの基材を一定押出圧力を加え、各温度に
おける細管の流出速度を測定し、図２に示した。Test Example 3 (Heat Resistance Test) A constant extrusion pressure was applied to the base material of each test sample, and the outflow rate of the capillary at each temperature was measured, and is shown in FIG.
図１
ｃｍ／ｓｅｃ
図１に示す通り、実施例は参考例に比較し温度における
流出速度が非常に小さく、耐熱性に優れる温熱貼付剤並
びに発熱部材用粘着剤であることが示された。Fig. 1 cm/sec As shown in Fig. 1, the outflow velocity of the example was very small compared to the reference example, indicating that it was a thermal patch and a pressure-sensitive adhesive for heat-generating members with excellent heat resistance.
試験例４（柔軟性試験）
１号型ダンベル状で調整した試験サンプルを、３００ｍ
ｍ／ｍｉｎの引張速度で強度と伸びを測定し図３に示し
た。Test example 4 (flexibility test) A test sample prepared in the shape of a No. 1 dumbbell was
The strength and elongation were measured at a tensile rate of m/min and are shown in FIG.
図２
ｋｇ ／ ｃｔＡ
２００ ４００ ６００ ８００ １０００（χ）図２
より実施例１は参考例２に比較して、弱い力で伸長し、
更に破断時における伸びと強度が大きく柔軟性に優れた
温熱貼付剤である。Figure 2 kg/ctA 200 400 600 800 1000 (χ) Figure 2
Therefore, Example 1 expanded with a weaker force than Reference Example 2,
Furthermore, it is a thermal patch with high elongation and strength at break, and excellent flexibility.
実施例及び試験例からもわかる通り、本発明の温熱貼付
剤は
■早い温感発現
■皮膚に追従しうる柔らかい粘着特性
■汗等の分泌物の吸収
■熱に対して安定な特性
■皮膚に対する副作用（気触れ等）の緩和等の機能を保
持した、従来にない優れた自若性の温熱貼付剤並びに発
熱部材用粘着剤であり、薬物を含有しない場合は、特に
肩こり、腰痛、打ち身。As can be seen from the examples and test examples, the thermal patch of the present invention has: ■ Quick onset of warming sensation ■ Soft adhesive properties that can follow the skin ■ Absorption of secretions such as sweat ■ Stable properties against heat ■ Properties that are good for the skin It is an unprecedented and superior self-retaining thermal patch and adhesive for heat-generating parts that retains functions such as alleviating side effects (sensitivity, etc.), and when it does not contain drugs, it is especially effective against stiff shoulders, lower back pain, and bruises.
捻挫等の疾患に対する治療剤として有用である。It is useful as a therapeutic agent for diseases such as sprains.
又、各々の薬物を含有した場合においても上記の機能を
有し、それぞれの薬効発現性をより向上させるものであ
り、医薬産業上非常に有用である。Moreover, even when each drug is contained, it has the above-mentioned functions and further improves the expression of each drug's efficacy, making it very useful in the pharmaceutical industry.
手続補正書（Ｂ Ｑ ）
昭和６３年 ７月ｔｔ１診
特許庁長官 吉 １）文 ｔａ 殿１、事件の表
示
昭和６３年 特許願第１２９３８８号
２、 発明の名称
温熱貼付剤
３、補正をする者
６、補正の内容
本願願書及び明細書中、下記の訂正を致します。Procedural amendment (BQ) July 1986 tt1 Examination by the Commissioner of the Patent Office Yoshi 1) Written by TA 1, Indication of the case 1988 Patent Application No. 129388 2, Name of the invention Thermal patch 3, Person making the amendment 6. Contents of amendment The following corrections will be made to the application and specification.
（１１願書を「別紙の通り」補正する。(The application form No. 11 is amended as per the attached sheet.
（２） 明細書を「別紙の通り」補正する。(2) Amend the specification “as per the attached sheet”.
明細書
１、発明の名称
温熱貼付剤
２、特許請求の範囲
１、発熱部材にＡ−Ｂ−Ａ型ブロック共重合体、脂環族
系石油樹脂、軟化剤及び吸水高分子よりなる粘着剤を付
与した温熱貼付剤。Description 1, Name of the invention Thermal patch 2, Claim 1, The heat generating member includes an adhesive consisting of an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, and a water-absorbing polymer. Thermal patch applied.
２、発熱部材にＡ−Ｂ−Ａ型ブロック共重合体１０〜３
０重量部、脂環族系石油樹脂１０〜５０重量部、軟化剤
１０〜５０重量部及び吸水高分子１〜１０重量部よりな
る粘着剤を付与した温熱貼付剤。2. A-B-A type block copolymer 10-3 in heat generating member
0 parts by weight, 10 to 50 parts by weight of an alicyclic petroleum resin, 10 to 50 parts by weight of a softener, and 1 to 10 parts by weight of a water-absorbing polymer.
３、 Ａ−Ｂ−Ａ型ブロック共重合体、脂環族系石油
樹脂、軟化剤及び吸水高分子よりなる発熱部材用粘着剤
。3. An adhesive for a heat-generating member comprising an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, and a water-absorbing polymer.
４、 Ａ −Ｂ −Ａ型ブロック共重合体１０〜３０
重量部、脂環族系石油樹脂１０〜５０重量部、軟化剤１
０〜５０重量部及び吸水高分子１〜１０重量部よりなる
発熱部材用粘着剤。4, A-B-A type block copolymer 10-30
Parts by weight, 10-50 parts by weight of alicyclic petroleum resin, 1 part by weight of softener
An adhesive for a heat-generating member comprising 0 to 50 parts by weight and 1 to 10 parts by weight of a water-absorbing polymer.
５、発熱部材にＡ−Ｂ−Ａ型ブロック共重合体、脂環族
系石油樹脂、軟化剤、吸水高分子及び薬物を含有させた
粘着剤を付与した温熱貼付剤。5. A thermal patch in which a heat-generating member is provided with an adhesive containing an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, a water-absorbing polymer, and a drug.
３、発明の詳細な説明
〔産業上の利用分野〕
本発明は人体皮膚に適用することを目的とした自着性の
優れた温熱貼付剤並びに発熱部材用粘着剤を提供するこ
とにある。3. Detailed Description of the Invention [Industrial Field of Application] The object of the present invention is to provide a thermal patch with excellent self-adhesive properties and an adhesive for a heat-generating member, which are intended to be applied to human skin.
従来より、空気又は酸素の存在によって発熱する発熱層
及び粘着層からなる、温熱貼付剤が検討されている。例
えば特開昭５０−５４１８８号には鉄粉等よりなる発熱
部材と湿布部材よりなる温湿布構造物が、特開昭５３−
４７１５４号にはアルカリ金属の硫化物よりなる発熱剤
と湿布剤よりなる温熱湿布剤が、更に特開昭６２−１０
３０１４号には発熱体と粘着剤を組み合わせた温熱プラ
スターが、それぞれ開示されている。BACKGROUND ART A thermal patch consisting of a heat generating layer and an adhesive layer that generate heat in the presence of air or oxygen has been studied. For example, JP-A-50-54188 discloses a hot compress structure consisting of a heat-generating member made of iron powder or the like and a compress member.
No. 47154 discloses a heating poultice consisting of an exothermic agent made of an alkali metal sulfide and a poultice;
No. 3014 discloses a thermal plaster that combines a heating element and an adhesive.
しかし、これらの温熱貼付剤において、イ）粘着力が弱
いため、皮膚に貼付する場合粘着テープ等で止める補助
手段が必要である。However, these thermal patches have (a) weak adhesive strength, so when they are applied to the skin, an auxiliary means such as adhesive tape is required to fix them.
口）湿布剤にあっては含、有する水の影響のため熱伝導
が悪く貼付時に冷感を感じ、更に温感を感じるまでのラ
グタイムがある。(Note) Poultices have poor heat conduction due to the influence of water they contain, resulting in a cold sensation when applied, and a lag time until a warm sensation is felt.
ハ）油性の粘着剤を用いた場合、剥離時の角質剥離によ
る気触れが発生する場合がある。c) If an oil-based adhesive is used, there may be a feeling of discomfort due to exfoliation of the dead skin during peeling.
二）湿布剤と皮膚との間に、発熱による汗等の分泌物が
貯留しこれが気触れの原因となる。2) Secretions such as sweat due to fever accumulate between the poultice and the skin, causing irritation.
ホ）発熱により、皮膚と接触している粘着剤に変化が起
き、ダレ、膏体のはみだし等が起きる場合がある。e) Due to heat generation, changes may occur in the adhesive that is in contact with the skin, resulting in sagging, oozing of the paste, etc.
等の問題があり、未だ理想的な温熱貼付剤並びに発熱部
材用粘着剤が出現していないのが現状である。Due to these problems, the current situation is that ideal thermal patches and adhesives for heat-generating members have not yet appeared.
そこで本願発明者らは、これらの問題を解決するために
鋭意研究を重ねた結果、Ａ−Ｂ−Ａ型ブロック共重合体
、脂環族系石油樹脂、軟化剤及び吸水高分子よりなる粘
着剤を使用することで、１、貼付時より温感を怒しる熱
伝導性を保持２、皮膚の動きに追従しうる柔らかい粘着
特性
３、気触れの原因となる汗等の分泌物を吸収する
４、熱に対して安定であり、ダレ、膏体のはみだし等が
ない
５、皮膚に対する副作用（気触れ）の緩和等の特性を保
持した、まさに理想的な温熱貼付剤並びに発熱部材用粘
着剤となることを見い出し、本発明としたのである。In order to solve these problems, the inventors of the present application have conducted intensive research and found that an adhesive consisting of an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, and a water-absorbing polymer. By using this, 1. It maintains thermal conductivity that increases the sensation of warmth when applied. 2. It has soft adhesive properties that can follow the movement of the skin. 3. It absorbs secretions such as sweat that cause skin irritation. 4. It is stable against heat and does not sag or extrude from the plaster. 5. It is an ideal thermal patch and adhesive for heat-generating parts that maintains properties such as alleviating side effects (feelings) on the skin. We have found that this is the case, and have devised the present invention.
本発明は、温熱貼付剤並びに発熱部材用粘着剤に最も適
した粘着剤を見い出し温熱貼付剤としたことにある。The present invention consists in finding an adhesive that is most suitable for a thermal patch and an adhesive for a heat-generating member, and making it into a thermal patch.
次に本発明の構成成分について詳しく説明する。Next, the constituent components of the present invention will be explained in detail.
Ａ−Ｂ−Ａ型ブロック共重合体とは、モノビニル置換芳
香族化合物Ａと共役ジオレフィン共重合体Ｂとのブロッ
ク共重合体であり、具体的にはカリフレックスＴＲ−１
１０１カリフレックスＴＲ−１１０７、カリフレックス
ＴＲ−１１１１（シェル化学製）等、フィリップペトロ
リアム製のツルブレン４１８等であり、その配合量は粘
着剤組成物中１０〜３０重量部であり、好ましくは１５
〜２５重量部である。The A-B-A type block copolymer is a block copolymer of monovinyl-substituted aromatic compound A and conjugated diolefin copolymer B, and specifically, Cariflex TR-1
101 Kaliflex TR-1107, Kaliflex TR-1111 (Shell Chemical Co., Ltd.), Trubulen 418 manufactured by Philip Petroleum, etc., and the amount thereof is 10 to 30 parts by weight in the adhesive composition, preferably 15 parts by weight.
~25 parts by weight.
吸水高分子とは、自重の１０倍以上の水を吸収しゲル化
膨潤するものであり、例えば水溶性ポリマーに軽度な架
橋結合を導入した吸水高分子が、適宜単独もしくは２種
以上の混合でもって処方される。具体的にはサンウェッ
トＩＭ−３００、サンウェットＩＭ−３００ＭＰＳ、サ
ンウェット■Ｍ−１０００、サンウェットＩＭ−１００
０ＭＰＳ（三洋化成製）等、アクアキープ４Ｓ、アクア
キープ４ＳＨ（製鉄化学製）等、スミカゲル５Ｐ−５２
０、スミカゲルＮ−１０４０（住人化学製）等、Ｋｌゲ
ル２０１−に、Ｋｌゲル−２０１に−Ｆ２（クラレ製）
等、アラソーブ８００、アラソーブ８００Ｆ （荒川化
学製）等であり、中でもサンウェットＩＭ−３００ＭＰ
Ｓ、サンウェットＩＭ−１０００ＭＰＳ、スミカゲルＮ
Ｐ−１０２０、スミカゲルＮＰ−１０４０、Ｋｌゲル−
２０１に−Ｆ２、アラソーブ８００Ｆ等は特に好ましい
。配合量としては、粘着剤組成物中１〜１０重量部であ
り、好ましくは２〜８重量部である。A water-absorbing polymer is one that absorbs more than 10 times its own weight of water and gels and swells. For example, a water-absorbing polymer that has a mild crosslinking bond introduced into a water-soluble polymer can be used alone or as a mixture of two or more. It is prescribed. Specifically, Sunwet IM-300, Sunwet IM-300MPS, Sunwet M-1000, Sunwet IM-100.
0MPS (manufactured by Sanyo Chemical Co., Ltd.), Aqua Keep 4S, Aqua Keep 4SH (manufactured by Steel Chemical Co., Ltd.), etc., Sumikagel 5P-52
0, Sumikagel N-1040 (manufactured by Sumika Gel), etc., Kl Gel 201-, Kl Gel-201 -F2 (manufactured by Kuraray)
etc., Arasorb 800, Arasorb 800F (manufactured by Arakawa Chemical), among others, Sunwet IM-300MP.
S, Sunwet IM-1000MPS, Sumikagel N
P-1020, Sumikagel NP-1040, Kl gel-
201, -F2, Arasorb 800F, etc. are particularly preferred. The blending amount is 1 to 10 parts by weight, preferably 2 to 8 parts by weight, in the pressure-sensitive adhesive composition.
脂環族系石油樹脂とは、環状骨格を持った石油系樹脂で
あり、具体的にはアルコンＰ−８５、アルコンＰ−１０
０、アルコンＰ−１２５（荒川化学製）等、フィントン
（日本ゼオン製）、エスコレッッ３０００ （エクソン
製）等であり、その配合量は１０〜５０重量部であり、
好ましくは２５〜４５重量部である。Alicyclic petroleum resin is a petroleum resin with a cyclic skeleton, specifically Alcon P-85, Alcon P-10.
0, Alcon P-125 (manufactured by Arakawa Chemical Co., Ltd.), Finton (manufactured by Nippon Zeon Co., Ltd.), Escolette 3000 (manufactured by Exxon Co., Ltd.), etc., and the blending amount thereof is 10 to 50 parts by weight,
Preferably it is 25 to 45 parts by weight.
軟化剤としては、高級脂肪酸、液化ゴム、鉱油等が用い
られ、その配合量としては、１０〜５０重量部、好まし
くは２５〜４５重量部である。As the softening agent, higher fatty acids, liquefied rubber, mineral oil, etc. are used, and the amount thereof is 10 to 50 parts by weight, preferably 25 to 45 parts by weight.
その他使用目的に応じて、従来公知の老化防止剤、無機
充填剤、酸化防止剤等が適宜適量配合される。In addition, conventionally known anti-aging agents, inorganic fillers, antioxidants, etc. may be blended in appropriate amounts depending on the purpose of use.
以上のようにして、得られた粘着剤を発熱部材と組み合
わせて、本願発明の温熱貼付剤とするわけであるが、こ
こで発熱部材の種類は別に制約はな（、従来公知の発熱
を有する部材であればすべて適用できるものである。As described above, the obtained adhesive is combined with a heat-generating member to produce the thermal patch of the present invention, but there are no particular restrictions on the type of heat-generating member (including conventionally known heat-generating members). It can be applied to any member.
例えば電気利用の発熱部材、乾電池又は太陽電池等を使
用した発熱部材又はペーパー状の電池、あるいはもぐさ
や昔から使用されているカイロ部材や化学発熱を利用し
た発熱カイロ等が挙げられる。又、化学発熱を利用した
発熱カイロの原料としては、例えば特開昭５０−１０５
５６２号公報、実開昭５０−９’７２８９号公報、特開
昭５０−２３０６４号公報、特開昭５０−４０４７７号
公報、実開昭５５−５９６１６号公報、特公昭６０−１
２３８１号公報、特公昭６１−８１１６号公報、特公昭
６３−２４０３０号公報等に記載のものが使用されるが
、これら引用公報記載のものに限定はされず、これら以
外の公報又は文献記載のものも当然使用される。尚、本
発明における発熱部材として特に好ましいのは、化学発
熱型の発熱カイロ型のものが携帯上より便利である。そ
の組成としては鉄粉系、反応助剤、水及び保水剤から構
成されるもので、空気及び水の共存下で発熱を生起する
物質が好んで使用される。具体的には鉄粉、還元鉄粉、
活性炭、アルミナ、シリカゲル、木炭、吸水性高分子、
塩化ナトリウム、塩化カリウム、塩化マグネシウム、塩
化鉄、酢酸、クロル酢酸、水、アクリル系吸水高分子等
の発熱原料を適宜配合処方した組成物であり、本発明に
おいて使用する発熱剤量は１〜２ ｇ ／ ｃｎｌ程度
が適当である。又、発熱剤の温度条件としては粘着剤層
の熱安定性を破壊しないことがもっとも重要であり、極
度の高温状態は好ましくない。そこで、本発明の温度設
定としては粘着剤表面温度が６０℃以下がよく、好まし
くは５０℃以下、更に好ましい状態としては４５℃以下
がもっともよい。又、遠赤外線効果を期待するうえで発
熱組成中にセラミックスの含有や発熱部材層と粘着剤層
の間にセラミックスを挿入した層を設けてもよい。Examples include heat-generating members using electricity, heat-generating members using dry batteries or solar cells, or paper batteries, warmer members that have been used for a long time, and heat-generating body warmers that utilize chemical heat generation. In addition, as raw materials for heat-generating hand warmers that utilize chemical heat generation, for example, Japanese Patent Application Laid-Open No. 50-105
No. 562, Japanese Utility Model Publication No. 50-9'7289, Japanese Unexamined Utility Model Publication No. 50-23064, Japanese Unexamined Utility Model Publication No. 40477-1977, Japanese Utility Model Publication No. 55-59616, Japanese Unexamined Utility Model Publication No. 1987-1
Those described in Japanese Patent Publication No. 2381, Japanese Patent Publication No. 61-8116, Japanese Patent Publication No. 63-24030, etc. are used, but the materials described in these cited publications are not limited, and those described in other publications or documents are used. Of course things are also used. It should be noted that a particularly preferred heat generating member in the present invention is a chemical heating type heat generating body warmer type, which is more convenient to carry. Its composition consists of iron powder, a reaction aid, water, and a water retention agent, and substances that generate heat in the coexistence of air and water are preferably used. Specifically, iron powder, reduced iron powder,
activated carbon, alumina, silica gel, charcoal, water-absorbing polymer,
It is a composition in which exothermic raw materials such as sodium chloride, potassium chloride, magnesium chloride, iron chloride, acetic acid, chloroacetic acid, water, and acrylic water-absorbing polymer are appropriately mixed and formulated, and the amount of exothermic agent used in the present invention is 1 to 2. g/cnl is appropriate. Furthermore, the most important temperature condition for the exothermic agent is not to destroy the thermal stability of the adhesive layer, and extremely high temperatures are not preferred. Therefore, the temperature setting in the present invention is such that the pressure-sensitive adhesive surface temperature is preferably 60°C or lower, preferably 50°C or lower, and most preferably 45°C or lower. Furthermore, in order to expect a far-infrared effect, ceramics may be included in the heat-generating composition, or a layer with ceramics inserted between the heat-generating member layer and the adhesive layer may be provided.
このようにして得られた温熱貼付剤は、肩こり、腰痛、
打ち身、捻挫等の疾患に使用され、温熱による治療効果
を充分期待できるものであり、又、使用上特に問題を生
じていた気触れの発生を、本発明の温熱貼付剤に吸汗性
を持たせることにより著しく抑制させたものである。The thermal patch obtained in this way can be used to treat stiff shoulders, lower back pain,
The thermal patch of the present invention is used for diseases such as bruises and sprains, and can be expected to have a sufficient therapeutic effect due to heat.The thermal patch of the present invention has sweat absorption properties to prevent the occurrence of skin sensation, which has been a particular problem during use. This has significantly suppressed the
又、薬物としては経皮吸収可能な薬物を含有させ、温熱
医療用貼付剤として用いることができる。In addition, a transdermally absorbable drug may be included as a drug, and it can be used as a thermal medical patch.
例えば、皮膚刺激剤及び鎮痛消炎剤として、サリチル酸
、サリチル酸メチル、サリチル酸グリコール、！−メン
トール、カンフル、ハツカ油、チモール、ニコチン酸ベ
ンジルエステル、トウガラシエキス、カブサイシン、ノ
ニル酸ワニアルアミド、フルビナク、フルフェナム酸ブ
チル、ピロキシカム、インドメタシン、ケトプロフェン
、プラノプロフェン、フェプラゾン、ロキソプロフェン
、アンツェナフナトリウム、オキサプロジン、エモルフ
プゾン、フェンチアザツク、ジクロツェナフナトリウム
、ジフルニサール、イブプロフェンピコノール、ペンダ
ザック、及びスプロフェン、並びにこれらのエステル誘
導体、あるいは塩酸ブブレノルフィン、ペンタゾシン、
酒石酸ブトルファノール等。For example, salicylic acid, methyl salicylate, glycol salicylate, as a skin irritant and analgesic anti-inflammatory agent! - Menthol, camphor, pepper oil, thymol, nicotinic acid benzyl ester, capsicum extract, kabsaicin, nonylic acid vanialamide, flubinac, butyl flufenamate, piroxicam, indomethacin, ketoprofen, pranoprofen, feprazone, loxoprofen, anzenaf sodium, oxaprozin, Emorphupzone, fentiazac, diclozenaf sodium, diflunisal, ibuprofenpiconol, pendazac, and suprofen, and their ester derivatives, or bubrenorphine hydrochloride, pentazocine,
butorphanol tartrate etc.
中枢神経作用剤（睡眠鎮静剤、抗てんかん剤、精神神経
用剤）として、フルフェナジン、チオリダジン、ジアゼ
パム、クロルプロマジン、ニトラゼバム、エスタゾラム
、トリアゾラム、ニメタゼパム、フルニトラゼバム、ハ
ロセキサシラム、フルラゼバム、クロナゼパム、プロベ
リジアジン、プロクロルペラジン、アルブラシラム、オ
キサゼパム、オキサゾラム、クロキサゾラム、プラゼパ
ム、フルタゾラム、メキサゾラム、ロラゼバム、フルジ
アゼパム、プロマゼバム、メタゼパム等。Central nervous system acting agents (sedative sleep agents, antiepileptic agents, psychiatric agents) include fluphenazine, thioridazine, diazepam, chlorpromazine, nitrazebam, estazolam, triazolam, nimetazepam, flunitrazebam, halosexacillam, flurazebam, clonazepam, proberidiazine, prochlorpera. Gin, albrasulam, oxazepam, oxazolam, cloxazolam, prazepam, flutazolam, mexazolam, lorazebam, fludiazepam, promazebam, metazepam, etc.
利尿剤としてハイドロサイアザイド、ベンドロフルナサ
イアザイド、エチアジド、シクロペンチアジド、ヒドロ
クロロチアジド、ペンフルチド、メチクロチアジド、フ
ロセミド、メトラゾン、ポリチアシト、ペンドロフルメ
チアジド等。Diuretics include hydrothiazide, bendroflunathiazide, ethiazide, cyclopenthiazide, hydrochlorothiazide, penflutide, methyclothiazide, furosemide, metolazone, polythiacitide, pendroflumethiazide, etc.
血圧降下剤として、クロニジン、アルサーオキシロン、
レシナミン、メシル酸ジヒドロエルゴトキシン、レセル
、ピンプラゾシン、カプトプリル、ピンドロール、マレ
イン酸エナラプリル等。As antihypertensive agents, clonidine, altheroxirone,
Resinamine, dihydroergotoxin mesylate, Resel, pinprazosin, captopril, pindolol, enalapril maleate, etc.
冠血管拡張剤としてニトログリセリン、ニトログリコー
ル、イソソルバイトシナイトレート、塩酸ババベリン、
ジピリダモール、エフロキサート、トリメタシン、ニコ
ランジル、シンナリジン、ナイリドン、モルシドミンニ
フエジピン等。Coronary vasodilators include nitroglycerin, nitroglycol, isosorbite cinitrate, bababerine hydrochloride,
Dipyridamole, efloxate, trimetacin, nicorandil, cinnarizine, nyridone, molsidomine nifedipine, etc.
鎮咳去痰剤としてリン酸コデイン、リン酸ジヒドロコデ
イン、塩酸エフェドリン、塩酸クロルプレナリン、臭化
水素酸フェノチロール、硫酸サルブタモール、リン酸ジ
メモルファン、塩酸アゼラスチン、塩酸クレンブテロー
ル、塩酸ツロブテロール、塩酸トリメトキノール、塩酸
プロカテロール、塩酸ブロムヘキシン、トラニラスト、
ヒベンズ酸チペピジン、フマル酸ケトチフェン、フマル
酸フォルモチロール、リン酸ペンスプロペリン、グリチ
ルレチン酸等。As an antitussive expectorant: codeine phosphate, dihydrocodeine phosphate, ephedrine hydrochloride, chlorprenaline hydrochloride, phenotyrol hydrobromide, salbutamol sulfate, dimemorphan phosphate, azelastine hydrochloride, clenbuterol hydrochloride, tulobuterol hydrochloride, trimethoquinol hydrochloride, procaterol hydrochloride, Bromhexine hydrochloride, tranilast,
Tipepidine hibenzate, ketotifen fumarate, formotyol fumarate, pensproperine phosphate, glycyrrhetinic acid, etc.
抗ヒスタミン剤として塩酸ジフェンヒドラミン、塩酸ト
リプロリジン、塩酸イソチペンジル、塩酸プロメタシン
、マレイン酸クロルフェニラミン、塩酸シブ口へブタジ
ン、フマル酸りレマスチン、マレイン酸カルビノキサミ
ン、マレイン酸ジメチンデン等。Antihistamines include diphenhydramine hydrochloride, triprolidine hydrochloride, isothipendyl hydrochloride, promethacin hydrochloride, chlorpheniramine maleate, hebutadine hydrochloride, lemastine fumarate, carbinoxamine maleate, dimethindene maleate, etc.
不整脈用剤としてアルプレノロール、オクスプレノロー
ル、ブクモロール、ブプラノロール、ピンドロール、イ
ンデノロール、カルテオロール、ブクモロール、プロプ
ラノロール、チモロール等。Arrhythmia agents include alprenolol, oxprenolol, bucumolol, bupranolol, pindolol, indenolol, carteolol, bucumolol, propranolol, timolol, etc.
強心剤としてジキタリス、ユビデカレノン、ジゴキシン
、メチルジゴキシン、デストラノシド等。Cardiotropes include digitalis, ubidecarenone, digoxin, methyldigoxin, and destranoside.
性ホルモンとしてエストラジオールエナンテート、エス
トラジオールシピネート、レボノルゲストレル、エスト
ラジオール等。Estradiol enanthate, estradiol cipinate, levonorgestrel, estradiol, etc. as sex hormones.
副腎皮膚ホルモン剤として酢酸ヒドロコルチゾン、ヒド
ロコルチゾン、プレドニゾロン、トリアムシノロンアセ
トニド、デキサメタシンリン酸エステル、メチルプレド
ニゾロン、酢酸ダイクロリンアセトニド、酢酸デキサメ
タシン、デキサメクゾン、フルオロメトロン、リン酸ベ
タメタシンナトリウム、ベタメタシン、吉草酸ベタメタ
シン、プロピオン酸ベクロメタゾン、フルドロキシコル
チド、酪酸ヒドロコルチゾン、ジプロピオン酸ベタメタ
シン、フルオシノニド、プロピオン酸クロベタゾール、
吉草酸ジフルコルトロン、ハルジノニド、アムシノニド
、吉草酸プレドニゾロン等。Adrenal skin hormones: hydrocortisone acetate, hydrocortisone, prednisolone, triamcinolone acetonide, dexamethacin phosphate, methylprednisolone, dichlorine acetate, dexamethacin acetate, dexamethasone, fluorometholone, betamethacin sodium phosphate, betamethacin, valeric acid Betamethacin, beclomethasone propionate, fludroxycortide, hydrocortisone butyrate, betamethacin dipropionate, fluocinonide, clobetasol propionate,
Diflucortolone valerate, haldinonide, amcinonide, prednisolone valerate, etc.
局所麻酔剤としてリドカイン、アミノ安息香酸エチル、
塩酸プロ力イン、ジブカイン、プロ力イン等が挙げられ
る。lidocaine, ethyl aminobenzoate, as a local anesthetic;
Examples include procytoin hydrochloride, dibucaine, procytoin, and the like.
これら薬効成分は、一種又は必要に応じて二種以上配合
されて用いられる。These medicinal ingredients may be used alone or in combination of two or more as necessary.
配合量としては薬効を期待できる量が好ましく、粘着剤
全体を１００重量部とした場合、０．００１〜２０重量
部の範囲内で適宜処方される。又、湿布薬として使用可
能な漢方薬のエキス、粉体等も当然使用できるものであ
る。The blending amount is preferably an amount that can be expected to have a medicinal effect, and is appropriately formulated within the range of 0.001 to 20 parts by weight when the entire adhesive is 100 parts by weight. Naturally, extracts, powders, etc. of Chinese herbal medicines that can be used as poultices can also be used.
このようにして薬効成分を配合した粘着剤を付与した温
熱貼付剤は特に長時間貼付しても気触れの原因と考えら
れる汗を充分に吸収するため、その発生を著しく抑制す
るものである。又、温熱効果もあり、人体皮膚に対する
薬物の経皮吸収が一段と向上し、薬効発現性が速く治療
効果においても好ましいものである。The thermal patch to which the adhesive containing medicinal ingredients has been applied in this way sufficiently absorbs sweat, which is considered to be the cause of dryness, even if it is applied for a long period of time, thereby significantly suppressing the occurrence of sweat. In addition, it has a thermal effect, which further improves the transdermal absorption of drugs into the human skin, and the onset of drug efficacy is fast, which is preferable in terms of therapeutic effects.
次に製造法としては、従来公知の方法で良く、例えばニ
ーダ−、ミキサー等の混練機を用い、１２０〜１６０℃
程度の温度で混練し、シート基材に展延するか、もしく
はいったん剥離処理の施された紙、フィルム等に展延し
、その後使用される基材に圧着転写して得られた粘着シ
ートを発熱体として張り合わせて製造することもできる
。Next, as a production method, a conventionally known method may be used, for example, using a kneader such as a kneader or mixer, and at a temperature of 120 to 160 °C.
The resulting adhesive sheet is kneaded at a certain temperature and spread on a sheet base material, or is first spread on release-treated paper, film, etc., and then pressure-transferred to the base material to be used. It can also be manufactured by laminating them together as a heating element.
このようにして製造された、温熱貼付剤は最終的には気
密性の包装形態で処理されることが望ましいものである
が、これは発熱体の発熱の仕方に応じた包装形態の対応
を取る必要があり、特に限定されるものではない。It is desirable that the thermal patch produced in this way is ultimately packaged in an airtight package, but the packaging should be adapted to the way the heating element generates heat. It is necessary and is not particularly limited.
以上、上述した本発明の温熱貼付剤は、以下の試験例、
実施例で述べる如く、
１）Ａ−Ｂ−Ａ型ブロック共重合体１０〜３０重量部
２）吸水高分子１〜１０重量部
３）脂環族系石油樹脂１０〜５０重量部４）軟化剤１０
〜５０重量部
又は１）〜４）の組成物に薬物配合による粘着剤が必須
であり、これを発熱体と組み合わせることにより、
■早い温域発現
■皮膚に追従しうる柔らかい粘着特性
■汗等の分泌物の吸収
■熱に対して安定な特性
■皮膚に対する副作用（気触れ等）の緩和等の特徴を有
し、正に理想的な温熱貼付剤並びに発熱部材用粘着剤と
なるのである。As mentioned above, the thermal patch of the present invention described above was tested in the following test examples,
As described in the examples, 1) 10 to 30 parts by weight of A-B-A type block copolymer 2) 1 to 10 parts by weight of water-absorbing polymer 3) 10 to 50 parts by weight of alicyclic petroleum resin 4) Softener 10
~50 parts by weight or an adhesive compounded with a drug in the composition of 1) to 4) is essential, and by combining this with a heating element, ■ Fast temperature development ■ Soft adhesive properties that can follow the skin ■ Sweat, etc. It has characteristics such as absorption of secretions, stability against heat, and alleviation of side effects on the skin (sensitivity, etc.), making it an ideal thermal patch and adhesive for heat-generating components.
次に、上述の作用及び効果を実施例及び試験例により更
に詳しく説明する。Next, the above-mentioned functions and effects will be explained in more detail using Examples and Test Examples.
実施例１
Ａ−Ｂ−Ａ型ブロック共重合体としてカリフレックスＴ
Ｒ−１１０７（シェル化学製）２５重量部と軟化剤とし
て流動パラフィン３０重量部、脂環族系石油樹脂として
アルコン（荒用化学製）４０重量部をニーグー中１６０
℃にて混練、その後吸水高分子としてサンウェットＩＭ
−３００ＭＰＳ（三洋化成製）５重量部を添加混合し、
不織布に３５０μ−の厚さになるように展延したものを
、所望の大きさに切断後、発熱体と張り合わせ本願発明
の温熱貼付剤とした。このものを貼付したところ、貼付
後３分で温域を感じ初め、６時間にわたって適度な温感
が持続した。又、剥離後の皮膚気触れも皆無であった。Example 1 Califlex T as an A-B-A type block copolymer
25 parts by weight of R-1107 (made by Shell Chemical Co., Ltd.), 30 parts by weight of liquid paraffin as a softener, and 40 parts by weight of Alcon (made by Arayo Chemical Co., Ltd.) as an alicyclic petroleum resin were mixed in 160 parts by weight of Niegu.
Knead at ℃, then use Sunwet IM as a water-absorbing polymer.
- Add and mix 5 parts by weight of 300MPS (manufactured by Sanyo Chemical),
The nonwoven fabric was spread to a thickness of 350 μm, cut into desired sizes, and laminated with a heating element to obtain the thermal patch of the present invention. When this product was applied, a warm sensation began to be felt 3 minutes after application, and a moderate warm sensation continued for 6 hours. Moreover, there was no skin irritation after peeling.
実施例２
Ａ−Ｂ−Ａ型ブロック共重合体としてカリフレックスＴ
Ｒ−１１０７（シェル化学製）２２重量部と添加剤とし
て流動パラフィン３３重量部、脂環族系石油樹脂として
アルコン（荒用化学製）３７重量部をニーダ−中１５０
℃にて混練、その後酸化チタン３重量部と吸水高分子と
してサンウェットＩＭ−３００ＭＰＳ （三洋化成製）
５重量部を添加今後し、実施例１と同様に処理して本発
明の温熱貼付剤とした。皮膚に貼付したところ実施例１
と同様であった。Example 2 Califlex T as an A-B-A block copolymer
22 parts by weight of R-1107 (made by Shell Chemical), 33 parts by weight of liquid paraffin as an additive, and 37 parts by weight of Alcon (made by Arayo Chemical) as an alicyclic petroleum resin were added to 150 parts by weight in a kneader.
Kneaded at ℃, then 3 parts by weight of titanium oxide and Sunwet IM-300MPS (manufactured by Sanyo Chemical) as a water-absorbing polymer.
After adding 5 parts by weight, the mixture was treated in the same manner as in Example 1 to obtain a thermal patch of the present invention. Example 1 when applied to the skin
It was the same.
参考例１
ゼラチン ４重量部ポリアクリル酸
ソーダ ５重量部グリセリン ２
０重量部ポリビニルピロリドン １重量部カオリ
ン １５重量部水
残部
上記の組成により、湿布剤を作成し、実施例１と同様に
して、温熱貼付剤とした。Reference example 1 Gelatin 4 parts by weight Sodium polyacrylate 5 parts by weight Glycerin 2
0 parts by weight Polyvinylpyrrolidone 1 part by weight Kaolin 15 parts by weight Water
A poultice was prepared using the remaining composition as described above, and a thermal patch was prepared in the same manner as in Example 1.
参考例２
カリフレックス↑Ｒ−１１０７２０重量部流動パラフィ
ン ２４重量部水添ロジン
３０重量部吸水性高分子 １重量部上記
の組成により、実施例１と同様に処理して温熱貼付剤と
した。Reference example 2 Cauliflex↑R-110720 parts by weight Liquid paraffin 24 parts by weight Hydrogenated rosin
30 parts by weight Water-absorbing polymer 1 part by weight With the above composition, a thermal patch was prepared in the same manner as in Example 1.
試験例１ （温感試験）
ボランティアの背中に本発明の実施例１及び参考例１の
温熱貼付剤を貼付し、その皮膚温度変化を温度センサー
にて測定した。その結果を表１に示す。Test Example 1 (Warming sensation test) The thermal patches of Example 1 and Reference Example 1 of the present invention were applied to the backs of volunteers, and changes in skin temperature were measured using a temperature sensor. The results are shown in Table 1.
表１
表１に示す通り、本発明の温熱貼付剤は、参考例に比較
し、早い温感発現を如実に示しており、本発明温熱貼付
剤並びに発熱部材用粘着剤の優秀さを裏付けるものであ
った。Table 1 As shown in Table 1, the thermal patch of the present invention clearly shows a rapid onset of warming sensation compared to the reference example, which confirms the excellence of the thermal patch of the present invention and the adhesive for heat-generating components. Met.
試験例２（吸水力試験）
各試験サンプル（実施例１．２及び比較例１より発熱体
を除いたもの）５Ｘ５ｃｍのものを水中に浸し、８時間
後に取り出しそのｍｍを測定し、増加した重量を元の重
量で除し、吸水した量を表２に示す。（尚、比較例１と
は、実施例１より吸水高分子を除いたものである。）
表２
結果より明らかな如く、本発明の粘着剤は、比較例に比
べきわだった吸水力を示した。Test Example 2 (Water Absorption Power Test) Each test sample (Example 1.2 and Comparative Example 1 without the heating element) 5 x 5 cm was immersed in water, taken out after 8 hours, measured in mm, and the increased weight. Table 2 shows the amount of water absorbed by dividing by the original weight. (Comparative Example 1 is Example 1 except that the water-absorbing polymer was removed.) Table 2 As is clear from the results, the adhesive of the present invention exhibited remarkable water-absorbing power compared to Comparative Example. .
試験例３ （耐熱性試験）
各試験サンプルの基材を一定押出圧力を加え、各温度に
おける細管の流出速度を測定し、第１図に示した。Test Example 3 (Heat Resistance Test) A constant extrusion pressure was applied to the base material of each test sample, and the outflow velocity of the capillary at each temperature was measured, and the results are shown in FIG.
第１図に示す通り、実施例は参考例に比較し温度におけ
る流出速度が非常に小さく、耐熱性に優れる温熱貼付剤
並びに発熱部材用粘着剤であることが示された。As shown in FIG. 1, the outflow rate of the example at different temperatures was much lower than that of the reference example, indicating that it was a thermal patch and a pressure-sensitive adhesive for heat-generating members with excellent heat resistance.
試験例４（柔軟性試験）
１母型ダンベル状で調整した試験サンプルを、３００
龍／ｌＴｌ１ｎの引張速度で強度と伸びを測定し第２図
に示した。Test Example 4 (Flexibility Test) 1 A test sample prepared in the shape of a mother-shaped dumbbell was
The strength and elongation were measured at the tensile rate of Ryu/lTl1n and are shown in FIG.
第２図より実施例１は参考例２に比較して、弱い力で伸
長し、更に破断時における伸びと強度が大きく柔軟性に
優れた温熱貼付剤である。As can be seen from FIG. 2, Example 1 is a thermal patch that stretches with a weaker force and has greater elongation and strength at break than Reference Example 2, and is excellent in flexibility.
実施例及び試験例からもわかる通り、本発明の温熱貼付
剤は
■早い温感発現
■皮膚に追従しうる柔らかい粘着特性
■汗等の分泌物の吸収
■熱に対して安定な特性
■皮膚に対する副作用（気触れ等）の緩和等の機能を保
持した、従来にない優れた自着性の温熱貼付剤並びに発
熱部材用粘着剤であり、薬物を含有しない場合は、特に
肩こり、腰痛、打ち身。As can be seen from the examples and test examples, the thermal patch of the present invention has: ■ Quick onset of warming sensation ■ Soft adhesive properties that can follow the skin ■ Absorption of secretions such as sweat ■ Stable properties against heat ■ Properties that are good for the skin It is an unprecedented self-adhesive thermal patch and adhesive for heat-generating parts that maintains the function of alleviating side effects (such as discomfort), and when it does not contain drugs, it is especially effective against stiff shoulders, lower back pain, and bruises.
捻捏等の疾患に対する治療剤として有用である。It is useful as a therapeutic agent for diseases such as torsion.
又、各々の薬物を含有した場合においても上記の機能を
有し、それぞれの薬効発現性をより向上させるものであ
り、医薬産業上非常に有用である。Moreover, even when each drug is contained, it has the above-mentioned functions and further improves the expression of each drug's efficacy, making it very useful in the pharmaceutical industry.
第１図は実施例１及び参考例２のサンプルの耐熱性試験
を示し、第２図は実施例１及び参考例２のサンプルの柔
軟性試験を示したものである。
第１図
ｃＪ／５ｅｃ
３０４０５０６０７０℃
第 ２ 図
ｋｇ／ｃｒＡ
２００４００６００８００１０００（Ｘ）手続補正書、
自え。
平成 １年５月２８日
特許庁長官 吉 １）文 毅 殿 ＼き！、事
件の表示
昭和６３年 特許願第１２９３８８号
２、発明の名称 温熱貼付剤
３、補正をする者
４、補正命令の日付 自発
５、補正の対象
（１） 明細書中、［３、発明の詳細な説明」の欄の
第３真下から第２行目の次に「※上記における気触れと
はカブレを意味する。」を挿入する。
（２）同書中、第６真上から第５行目の「（荒用化学Ｗ
）Ｊの前に「、アラソーブＳ−１００Ｊを挿入する。
（３）同書中、第１６真上から第５行目の「アルコン」
を「アルコンＰ−１００」と訂正する。
（４）同書中、第１６頁最後の行の「アルコン」をｒア
ルコンＰ−１００Ｊと訂正する。
（５）同書中、第１７真上から第４行目の「今後し」壱
「混合しｊと訂正する。
（６）同書中、第１７真上から第６行目の次に、下記ｅ
ｒ実施例３ｊを挿入する。
ｒ実施例３
Ａ−Ｂ−Ａ型ブロック共重合体としてカリフレックスＴ
Ｒ−１１０７（シェル化学製）２５重丘部と軟化剤とし
て流動パラフィン３０重量部、川原族系石油樹脂として
アルコンＰ−８５（荒用イ１学製）３９重量部をニーグ
ー中１６０℃にて混層その後吸水高分子としてサンウェ
ットｒＭ−ｉ。
００ＭＰＳ（三洋化成製）３重量部と酸化チタン３重量
部を添加混合し、実施例１同様に処理して； 本発明
の温熱貼付剤とした。皮膚に貼付したところ実施例１と
同様であった。ｊ
を
看
ｋ、FIG. 1 shows the heat resistance test of the samples of Example 1 and Reference Example 2, and FIG. 2 shows the flexibility test of the samples of Example 1 and Reference Example 2. Figure 1 cJ/5ec 3040506070℃ Figure 2 kg/crA 2004006008001000 (X) Procedural amendment,
Be yourself. May 28, 1999 Director General of the Japan Patent Office Yoshi 1) Moon Takeshi \ki! , Indication of the case 1988 Patent Application No. 129388 2, Title of the invention: Thermal patch 3, Person making the amendment 4, Date of amendment order Voluntary action 5, Subject of amendment (1) In the description, [3. Next to the second line from the third line of the "Detailed Explanation" column, insert "*The above description means blurring." (2) In the same book, in the 5th line from the 6th top, ``(Arayo Kagaku W
) Insert ", Arasorb S-100J" before J. (3) "Arcon" in the 5th line from the top of No. 16 in the same book.
is corrected to "Arcon P-100". (4) In the same book, "Arcon" in the last line of page 16 is corrected to rArcon P-100J. (5) In the same book, in the 4th line from the top of the 17th line, ``From now on'' is corrected as 1 ``Mixed j.'' (6) In the same book, in the 6th line from the 17th line right above, the following e
r Insert Example 3j. rExample 3 Califlex T as an A-B-A type block copolymer
25 parts by weight of R-1107 (manufactured by Shell Chemical), 30 parts by weight of liquid paraffin as a softening agent, and 39 parts by weight of Alcon P-85 (manufactured by Arayo Ilgaku) as a Kawahara family petroleum resin were heated at 160°C in a Ni-Goo. After the mixed layer, use Sunwet rM-i as a water-absorbing polymer. 3 parts by weight of 00MPS (manufactured by Sanyo Chemical Co., Ltd.) and 3 parts by weight of titanium oxide were added and mixed, and treated in the same manner as in Example 1 to obtain a thermal patch of the present invention. When applied to the skin, the result was the same as in Example 1. Look at j,
Claims (5)
系石油樹脂、軟化剤及び吸水高分子よりなる粘着剤を付
与した温熱貼付剤。1. A thermal patch in which a heat-generating member is provided with an adhesive consisting of an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, and a water-absorbing polymer.
０重量部、脂環族系石油樹脂１０〜５０重量部、軟化剤
１０〜５０重量部及び吸水高分子１〜１０重量部よりな
る粘着剤を付与した温熱貼付剤。2. A-B-A type block copolymer 10-3 for heat generating member
0 parts by weight, 10 to 50 parts by weight of an alicyclic petroleum resin, 10 to 50 parts by weight of a softener, and 1 to 10 parts by weight of a water-absorbing polymer.
、軟化剤及び吸水高分子よりなる発熱部材用粘着剤。3. An adhesive for heat generating members comprising an A-B-A type block copolymer, an alicyclic petroleum resin, a softener and a water-absorbing polymer.
脂環族系石油樹脂１０〜５０重量部、軟化剤１０〜５０
重量部及び吸水高分子１〜１０重量部よりなる発熱部材
用粘着剤。4. 10 to 30 parts by weight of A-B-A type block copolymer,
Alicyclic petroleum resin 10-50 parts by weight, softener 10-50 parts by weight
An adhesive for a heat-generating member, comprising parts by weight and 1 to 10 parts by weight of a water-absorbing polymer.
系石油樹脂、軟化剤、吸水高分子及び薬物を含有させた
粘着剤を付与した温熱貼付剤。5. A thermal patch in which a heat-generating member is provided with an adhesive containing an A-B-A type block copolymer, an alicyclic petroleum resin, a softener, a water-absorbing polymer, and a drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63129388A JPH0749042B2 (en) | 1988-05-25 | 1988-05-25 | Thermal patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63129388A JPH0749042B2 (en) | 1988-05-25 | 1988-05-25 | Thermal patch |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01297059A true JPH01297059A (en) | 1989-11-30 |
| JPH0749042B2 JPH0749042B2 (en) | 1995-05-31 |
Family
ID=15008345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63129388A Expired - Lifetime JPH0749042B2 (en) | 1988-05-25 | 1988-05-25 | Thermal patch |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0749042B2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| WO2005030897A1 (en) * | 2003-09-25 | 2005-04-07 | Ferric Inc. | Adhesive and thermal material stuck in use produced therewith |
| US6915798B2 (en) * | 1998-09-06 | 2005-07-12 | Ferric, Inc. | Method of forming a united exothermic medium and a heating element |
| US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
| JP2014054485A (en) * | 2012-09-14 | 2014-03-27 | Nitto Lifetech Kk | Adhesive member for skin stick-on body warmer and skin stick-on body warmer |
-
1988
- 1988-05-25 JP JP63129388A patent/JPH0749042B2/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262121B1 (en) | 1997-07-18 | 2001-07-17 | Teikoku Seiyaku Co., Ltd. | Oily patches for external use containing diclofenac sodium |
| US6915798B2 (en) * | 1998-09-06 | 2005-07-12 | Ferric, Inc. | Method of forming a united exothermic medium and a heating element |
| JP2000178186A (en) * | 1998-10-05 | 2000-06-27 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorption tape preparation |
| US6953590B1 (en) | 1998-10-05 | 2005-10-11 | Yutoku Pharmaceutical Ind. Co., Ltd. | Tape material for transcutaneous absorption |
| WO2005030897A1 (en) * | 2003-09-25 | 2005-04-07 | Ferric Inc. | Adhesive and thermal material stuck in use produced therewith |
| JP2005097447A (en) * | 2003-09-25 | 2005-04-14 | Mikasa Seiyaku Co Ltd | Adhesive and warming material for pasting using the same |
| JP2014054485A (en) * | 2012-09-14 | 2014-03-27 | Nitto Lifetech Kk | Adhesive member for skin stick-on body warmer and skin stick-on body warmer |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0749042B2 (en) | 1995-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5044078B2 (en) | UV shielding patch | |
| ES2281366T3 (en) | PREPARATIONS OF ADHESIVES. | |
| JP3184534B2 (en) | Medicinal compound comprising N-substituted-o-toluidine derivative and transdermal preparation | |
| WO2001052823A2 (en) | Compositions to effect the release profile in the transdermal administration of drugs | |
| JP2012020991A (en) | Transdermal absorption promoter, and external skin formulation thereof | |
| NO303262B1 (en) | Process for preparing a solid state matrix system for transdermal drug delivery | |
| KR20020011964A (en) | Sheet-form adhesive preparation | |
| JP3466305B2 (en) | Dissolving agent and external preparation containing the dissolving agent | |
| JP2008179564A (en) | Anti-inflammatory and analgesic plaster | |
| JPH0336805B2 (en) | ||
| JPH01297059A (en) | Warm heat sticking agent | |
| JPH10109945A (en) | Plasticizing agent and cataplasm containing the same | |
| JP3144895B2 (en) | Medical adhesive tape or sheet | |
| JP3188587B2 (en) | Thermal patch | |
| JP6867210B2 (en) | Patch | |
| ES2623533T3 (en) | Low irritation adhesive patch | |
| WO2019146614A1 (en) | Patch | |
| JPH0271745A (en) | Water-contained gel composition | |
| JP3525272B2 (en) | Skin sticking sheet | |
| JP2632838B2 (en) | External patch | |
| JPH01297069A (en) | Tacky adhesive agent composition | |
| JP3188586B2 (en) | Hot patch | |
| JP3224582B2 (en) | Transdermal formulation | |
| JPH085806B2 (en) | Transdermal formulation | |
| JPS63307819A (en) | Patch for percutaneous absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |